Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODEPREX vs MUCINEX DM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Cough suppression (FDA-approved)
Temporary relief of cough due to minor throat and bronchial irritation,Temporary relief of chest congestion and mucus buildup
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
Guaifenesin undergoes hepatic metabolism via oxidation and conjugation; dextromethorphan is metabolized by CYP2D6 to dextrorphan, an active metabolite.
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
92% (primarily to albumin)
Guaifenesin: approximately 30% to albumin. Dextromethorphan: approximately 50% to albumin and alpha-1-acid glycoprotein.
1.5-2.0 L/kg (extensive tissue distribution)
Guaifenesin: 0.8-1.5 L/kg. Dextromethorphan: 5-10 L/kg (extensive tissue binding).
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
Oral: Guaifenesin ~100% (tablet/syrup). Dextromethorphan ~11% (extensive first-pass metabolism; varies with CYP2D6 phenotype).
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
Cr Cl 30-50 m L/min: administer every 24 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not recommended. Peritoneal dialysis: not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to every 24 hours. Child-Pugh C: not recommended.
Not recommended for pediatric use (no safety and efficacy data established).
Children ≥12 years: same as adult. Children 6-11 years: guaifenesin 300 mg / dextromethorphan 15 mg orally every 12 hours, not to exceed 2 doses in 24 hours. Children <6 years: not recommended.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
Start at lower end of dosing range (e.g., one tablet every 24 hours) due to age-related renal and hepatic decline; monitor for CNS effects and constipation.
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
None
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
Do not use for persistent/chronic cough, cough with excessive phlegm, or cough due to smoking/asthma/COPD/emphysema,Serotonin syndrome risk with MAOIs or other serotonergic drugs,Dextromethorphan abuse potential,Hypersensitivity reactions
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
Concomitant use with MAOIs or within 14 days of MAOI therapy,Hypersensitivity to any component
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
No significant food-drug interactions. However, alcohol may potentiate CNS effects (drowsiness/dizziness) and should be avoided.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks at recommended doses. Avoid high doses of dextromethorphan due to potential serotonin reuptake inhibition and theoretical risk of fetal serotonin syndrome.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
Guaifenesin: excreted into breast milk in small amounts; no known adverse effects in infants at maternal therapeutic doses. Dextromethorphan: likely excreted into breast milk in low concentrations; M/P ratio not established. Use caution; monitor infant for sedation, respiratory depression, or constipation.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
No dose adjustment required for guaifenesin or dextromethorphan during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) are not clinically significant at standard doses. Use the lowest effective dose for the shortest duration.
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
Mucinex DM combines guaifenesin (expectorant) and dextromethorphan (antitussive). Guaifenesin is best taken with adequate fluid intake to thin mucus. Dextromethorphan is contraindicated with MAOIs and in patients with serotonin syndrome risk. Avoid use in patients with chronic cough due to smoking, asthma, or COPD without physician guidance.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
Take with a full glass of water to help loosen phlegm.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating machinery if drowsy or dizzy.,Do not use with other cough/cold medications containing dextromethorphan.,Stop use and consult doctor if cough persists >7 days or with fever, rash, or headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODEPREX vs MUCINEX DM, answered by our medical review team.
CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. MUCINEX DM is a Expectorant/Antitussive Combination that works by Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODEPREX and MUCINEX DM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. The standard adult dose of MUCINEX DM is: One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODEPREX and MUCINEX DM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. MUCINEX DM is classified as Category C. FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.